skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Restoration of normal phenotype in cancer cells

Patent ·
OSTI ID:872022
 [1];  [2]
  1. Berkeley, CA
  2. Oakland, CA
+ Show Author Affiliations

A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying .beta..sub.1 integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
DOE Contract Number:
AC03-76SF00098
Assignee:
Regents of University of California (Oakland, CA)
Patent Number(s):
US 5846536
OSTI ID:
872022
Country of Publication:
United States
Language:
English

References (6)

Inhibition of Cell Attachment, Invasion and Metastasis of Human Carcinoma Cells by Anti-integrin β 1 Subunit Antibody journal December 1992
Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity journal December 1991
Comparative evaluation of integrin ?- and ?-chain expression in colorectal carcinoma cell lines and in their tumours of origin journal October 1994
Development of anin vitro extracellular matrix assay for studies of brain tumor cell invasion journal January 1994
Another Anniversary for the War on Cancer journal March 1994
Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells journal October 1992

Similar Records

Related Subjects

restoration
normal
phenotype
cancer
cells
method
reversing
expression
malignant
described
comprises
applying
beta
integrin
function-blocking
antibody
assess
progress
therapy
human
breast
epithelial
shown
particularly
responsive
method comprises
cancer therapy
comprises applying
method comprise
epithelial cells
cancer cells
reversing expression
normal phenotype
function-blocking antibody
integrin function-blocking
malignant phenotype
/424/530/